David Shames

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

New England Journal of Medicine · 2018 · 2,932 citations

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Nature Medicine · 2018 · Last of 22 authors · Corresponding · 950 citations